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Edited by Richard MaraisAbstract Constitutive expression of the Pim-1 kinase prolongs
survival of cytokine-deprived FDCP1 cells, partly via mainte-
nance of Bcl-2 expression. Here, we show that Pim-1 colocalizes
and physically interacts with the pro-apoptotic Bad protein and
phosphorylates it in vitro on serine 112, which is a gatekeeper
site for its inactivation. Furthermore, wild-type Pim-1, but not a
kinase-deﬁcient mutant, enhances phosphorylation of this site in
FDCP1 cells and protects cells from the pro-apoptotic eﬀects of
Bad. Our results suggest that phosphorylation of Bad by Pim-1
is one of several mechanisms via which the Pim-1 kinase can
enhance Bcl-2 activity and promote cell survival.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Myeloid cells1. Introduction
The pim-1 proto-oncogene encodes a serine/threonine kinase
with three alternatively translated murine isoforms of 33, 34
and 44 kDa [1]. pim-1 is mainly expressed in cells of hemato-
poietic origin, where its transcription can be induced by mul-
tiple cytokines such as interleukins IL-2, IL-3 and IL-6 [2,3].
We have previously demonstrated that the Pim-1 kinase can in
turn participate in cytokine-induced signal transduction by
regulating activities of several transcription factors such as c-
Myb [4], NFATc1 [5] and signal transducer and activator of
transcription 5 [6].
Pim-1 has been shown to protect hematopoietic cells from
cell death caused by cytokine withdrawal, glucocorticoids or
genotoxins [7–9]. While the anti-apoptotic mechanisms of Pim-
1 are still largely unknown, we have previously shown that the
Pim-1-promoted survival of IL-3-deprived FDCP1 cells is as-* Corresponding author. Fax: +358-2-333-8000.
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DMEM, Dulbecco’s modiﬁed Eagle’s medium; FCS, fetal calf serum;
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0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.06.050sociated with sustained expression of bcl-2 mRNA and protein
levels, and that coexpression of antisense bcl-2 reduces the
protective eﬀects of the shorter Pim-1 isoforms [10]. These
results suggest involvement of additional mechanisms, possibly
targeting other Bcl-2 family members, such as Bad, which is a
pro-apoptotic protein regulated by phosphorylation [11]. Un-
phosphorylated Bad binds and thereby inactivates anti-apop-
totic family members, primarily Bcl-XL but also Bcl-2.
Cytokine-dependent phosphorylation of Bad on Ser112, Ser136
and/or Ser155 by several kinases such as Akt, protein kinase A
or Rsk impairs its binding to Bcl-XL and leads to sequestration
of Bad from the surface of mitochondria to the cytosol by the
14-3-3 protein [12–18]. Bad phosphorylation is a reversible
phenomenon antagonized by several protein phosphatases
such as PP2A [19]. Thus, diverse signaling pathways can
converge at the level of Bad phosphorylation in controlling cell
death or survival.
Here, we show that the Pim-1 kinase can physically interact
with Bad and phosphorylate it on Ser112 both under in vitro
and in vivo conditions. Pim-1 can also protect cytokine-de-
prived FDCP1 cells from Bad-promoted apoptosis, suggesting
that phosphorylation of Bad by Pim-1 is important, although
probably not suﬃcient for its ability to enhance cell survival
after cytokine withdrawal.2. Materials and methods
2.1. Plasmids
Prokaryotic glutathione S-transferase (GST)-Pim-1 fusion vectors
expressing the wild-type murine protein or the kinase-deﬁcient K67M
mutant have been described previously [5] as also pcDNA3-pim-1-
FLAG [4]. SV40 promoter-driven constructs encoding full-length Pim-
1 (pSV-pim-1) or an N-terminally truncated mutant (pSV-NT81) were
prepared by PCR from pLTR-pim-1 [5] into the pSV-poly vector [20].
Prokaryotic GST-Bad constructs were generated by transferring full-
length murine bad cDNA from pEBG-mBad (New England Biolabs)
into the pGEX-2T vector (Amersham Biosciences). Mutagenesis of
Ser112 and Ser136 to alanine residues in both prokaryotic and eukary-
otic GST-Bad vectors were introduced by PCR using the QuikChange
kit (Stratagene).
2.2. Cell culture and transfections
COS-7 cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM
L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin. Roswell
Park Medical Institute medium 1640 with equal supplements was used
to grow murine myeloid FDCP1 cell lines expressing neomycinblished by Elsevier B.V. All rights reserved.
Fig. 1. Pim-1 phosphorylates Bad on Ser112 in vitro. (A) Bacterially
produced wild-type (WT), S112A or S136A single mutants or S112A/
S136A double mutant (DM) of GST-Bad were incubated with wild-
type (WT) or kinase-deﬁcient K67M mutant (MT) of GST-Pim-1 in an
in vitro kinase assay. The phosphorylation products were analysed by
SDS–PAGE followed by autoradiography. GST alone ()) was used as
a negative control. (B) The amounts of proteins loaded on the gel were
visualized by silver staining. (C) Comparison of two-dimensional
tryptic phosphopeptide maps from the indicated samples of in vitro
phosphorylated wild-type or mutant GST-Bad proteins. The point of
application is marked with an x and the spots missing from mutant
samples with dotted circles.
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N-terminally truncated mutant of Pim-1 (FDCP1/NT81) [10]. 10%
WEHI-conditioned medium was used as a source of IL-3 for the IL-3-
dependent FDCP1 cells. For transient transfections, cells were elec-
troporated with GenePulser II (Bio-Rad).
2.3. Immunoblotting
100 lg aliquots of protein samples were mixed with buﬀer (20 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1
mM Na3VO4 and 1 mM PMSF). GST-Bad was precipitated with
glutathione–Sepharose beads (Amersham Biosciences) at 4 C. The
precipitates were fractionated by sodium dodecyl sulfate (SDS)–poly-
acrylamide gel electrophoresis (PAGE) and transferred to PVDF-
membrane (Millipore). For Western blotting, the membranes were
blocked, incubated ﬁrst with Bad or Phospho-Bad (Ser112, Ser136 or
Ser155) primary antisera and then with secondary horse-radish perox-
idase-linked antibodies (all from Cell Signaling Technology). Proteins
were visualized using the ECL+plus kit (Amersham Biosciences). Pim-
1 proteins were similarly recognized with the 19F7 anti-Pim-1 antibody
(Santa Cruz) and endogenous Bad with anti-Bad antibody (BD Bio-
sciences Pharmingen).
2.4. Phosphorylation assays
In vitro kinase assays were carried out as described [5]. For two-
dimensional tryptic phosphopeptide mapping, protein gels were ﬁxed
in 50% MetOH, dried on cellophane and exposed to ﬁlm. Proteins of
interest were cut out, digested overnight with 10 lg/ml TPCK-treated
trypsin (Sigma–Aldrich), and the resulting phosphopeptides separated
on two dimensions on thin layer cellulose plates [21]. For in vivo as-
says, cells were metabolically labeled with 1 mCi/ml of 32P-labeled
orthophosphate (Amersham Biosciences) in phosphate-free DMEM at
37 C for 2 h. GST-Bad precipitates prepared as above were frac-
tionated by SDS–PAGE and 32P-labeled proteins were detected by
autoradiography. Parallel samples were prepared without 32P-labeled
orthophosphate and analysed by Western blotting.
2.5. Protein interaction assays
For in vitro binding assays, puriﬁed GST or GST-Bad proteins
bound to glutathione–Sepharose beads were incubated ﬁrst with 1%
BSA to block non-speciﬁc binding and then with in vitro translated,
35S-labeled Pim-1 protein in binding buﬀer (150 mM NaCl, 50 mM
Tris–HCl, pH 7.5, 1 mM MgCl2, 2 mM CaCl2, 0.5% Triton X-100, 1
mM PMSF, 1 mM DTT, 1 mM Na3VO4 and 2 lg/ml aprotinin). After
washes, bound proteins were separated by SDS–PAGE and visualized
by Coomassie staining followed by autoradiography. For coprecipi-
tation assays, FLAG-tagged proteins from transfected COS-7 cells
were immunoprecipitated with anti-FLAG antibody (Kodak) as de-
scribed [5], separated by SDS–PAGE and immobilized onto PVDF
membrane. Coprecipitating GST-Bad proteins were analysed by im-
munoblotting with anti-Bad antiserum and the intensities of GST-Bad
versus IgG protein bands were determined by Imaging Research
MCID M5+ image analysis software.
2.6. Immunoﬂuorescence assays
COS-7 cells were transfected with Pim-1 and GST-Bad expression
vectors and plated on coverslips. 48 h after transfection, cells were
ﬁxed with 4% paraformaldehyde and permeabilized with 0.2% Nonidet
P-40. Subcellular distributions of Pim-1 and GST-Bad proteins were
visualized by staining with anti-Pim-1 antibody or anti-Bad antiserum
followed by TRITC-conjugated anti-mouse or FITC-conjugated anti-
rabbit antibodies (Zymed), respectively. Images were captured with
Zeiss LSM510 confocal microscope and scattergram plots were ac-
quired with Zeiss LSM image analyzer program.
2.7. Apoptosis assays
FDCP1/Neo and FDCP/Pim44 cells, transiently transfected with
GST-Bad constructs, were centrifuged through 2 ml of FCS to remove
cells that had died during electroporation. 24 h after transfection, cells
were washed once with PBS and IL-3 was withdrawn from the me-
dium. For 72 h, cell samples were collected at multiple time-points with
8 h intervals. Dead cells were stained with propidium iodide (PI),
counted with the FACScan ﬂow cytometer (Becton Dickinson) and
further analysed with the CellQuest software (Becton Dickinson).3. Results and discussion
3.1. Pim-1 phosphorylates Bad on Ser112 in vitro
Sequences surrounding Ser112 (L–R–R–M–S) and Ser136 (P–
R–P–K–S) of Bad slightly resemble the Pim-1 consensus target
site (K/R–K/R–R–K/R–L–S–X) identiﬁed by the use of syn-
thetic peptides [22]. To ﬁnd out whether the Pim-1 kinase can
phosphorylate Bad and thereby inactivate it, we performed in
vitro kinase assays with bacterially expressed GST-fusion
proteins of Bad and the 33 kDa isoform of Pim-1. Wild-type
GST-Pim-1 phosphorylated both itself and GST-Bad, but not
the GST only control, whereas no phosphate was incorporated
in the presence of the kinase-deﬁcient K67M mutant of Pim-1
(Fig. 1A). To be able to identify the phosphorylation target
site(s) for Pim-1 in Bad, we mutated Ser112 and/or Ser136 of
GST-Bad to alanine residues and used the mutants as sub-
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major eﬀect, whereas phosphorylation of Bad by Pim-1 was
strongly prohibited by the Ser112 mutation and almost com-
pletely abolished by a double mutation. Silver staining of the
gel conﬁrmed that all the Pim and Bad fusion proteins were
expressed to an equivalent extent (Fig. 1B).
Very similar results were obtained, when the in vitro phos-
phorylated GST-Bad proteins were cut out of the gel, sub-
jected to trypsin digestion and analysed by two-dimensional
phosphopeptide mapping (Fig. 1C). Several Pim-1-induced
phosphopeptide spots were observed for the wild-type GST-
Bad, the major ones of which disappeared with the S112A
mutation and the minor ones with the S136A mutation.
Hardly any spots were detectable anymore when both sites had
been mutated. Taken together, our in vitro results indicate that
Bad is a direct substrate for Pim-1, and that Pim-1 primarily
phosphorylates Bad on Ser112.
3.2. Pim-1 enhances phosphorylation of Bad on Ser112 also
within cells
To examine the ability of Pim-1 to phosphorylate Bad also
under in vivo conditions, COS-7 cells were transiently trans-
fected with expression vectors for GST-Bad and the 33 kDa
isoform of Pim-1. 24 h later, serum was withdrawn from half
of the transfected cells for 18 h to downregulate serum-induced
kinase activities. Cells grown in the presence or absence of
serum were then metabolically labeled with 32P-labeled or-
thophosphate for 2 h. In the presence of serum, equivalent
amounts of phosphate were incorporated into GST-Bad whe-
ther or not cells coexpressed Pim-1 (Fig. 2A, left lanes).
However, when serum had been withdrawn prior to labeling,
fresh phosphorylation of GST-Bad was diminished more eﬃ-Fig. 2. Pim-1 maintains Bad Ser112 phosphorylation in serum-starved
COS-7 cells. (A) GST-Bad (pEBG-mBad, 10 lg) was transiently ex-
pressed in COS-7 cells without or with 33 kD Pim-1 (pSV-poly or pSV-
pim-1, 4 lg). 24 h after transfection, serum was withdrawn from the
cells for 18 h and cells labeled with 32P-labeled orthophosphate for 2 h.
GST-Bad was then precipitated from cell lysates and its phosphory-
lation status visualized by autoradiography. (B) Steady-state phos-
phorylation of GST-Bad was visualized by immunoblotting with
phospho-Bad (Ser112 or Ser136) antisera from parallel unlabeled sam-
ples. Equal loading was conﬁrmed with anti-Bad antiserum.ciently from control cells than from Pim-1-expressing cells
(Fig. 2A, right lanes). To determine whether this was due to
phosphorylation of Bad by Pim-1 on Ser112 and/or Ser136, the
steady-state phosphorylation levels of these sites were analysed
from parallel samples by Western blotting with phosphoryla-
tion site-speciﬁc antibodies against Bad (Fig. 2B). Results from
this analysis indicated that Ser112 phosphorylation was much
more pronounced in Pim-1-expressing cells than in the control
cells, both in the absence and presence of serum (Fig. 2B). By
contrast, Pim-1 did not signiﬁcantly aﬀect Ser136 phosphory-
lation or GST-Bad expression levels. Thus, these results im-
plicate that Pim-1 is actively involved in intracellular
phosphorylation of Bad and that Ser112 of Bad is the prefer-
ential target site for Pim-1 also under in vivo conditions.
To further investigate phosphorylation of Bad by Pim-1
under more physiological conditions, we carried out Western
blot analyses with IL-3-dependent FDCP1 cell lines expressing
Neo (FDCP1/Neo) or the 44 kDa isoform of Pim-1 (FDCP1/Fig. 3. Constitutive expression of Pim-1 enhances Bad Ser112 phos-
phorylation in FDCP1 cells. (A) FDCP1/Neo, FDCP1/Pim44 or
FDCP1/NT81 cells were transiently transfected with the GST-Bad
expression vector (pEBG-mBad, 10 lg). 24 h after transfection, IL-3
was withdrawn and samples collected at indicated time-points. GST-
Bad was precipitated from cell lysates and its phosphorylation status
analysed with Phospho-Bad (Ser112 or Ser136) antisera. Ectopic or
endogenous Bad or Pim-1 expression levels were measured by anti-Bad
and anti-Pim-1 antisera. (B) FDCP1/Neo and FDCP1/Pim44 cells were
transfected with S112A mutant expression vector for GST-Bad
(pEBG-mBad S112A, 10 lg), and samples collected and analysed as
above.
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siently transfected with the GST-Bad expression vector re-
vealed that in the presence of IL-3, both Ser112 and Ser136 of
GST-Bad were phosphorylated to a similar extent in FDCP1/
Pim44 cells as in the FDCP1/Neo control cells (Fig. 3A and
data not shown). However, these two sites remained persis-
tently phosphorylated in FDCP1/Pim44 cells even after IL-3
withdrawal, while both of them were rapidly dephosphorylatedFig. 4. Pim-1 interacts with Bad in vitro and in vivo. (A) Wild-type Pim-
bacterially expressed GST or wild-type or mutant GST-Bad proteins. Pim-
analysed by SDS–PAGE followed by autoradiography. Ten percent of the in
(B) GST-Bad (pEBG-mBad, 6 lg) was expressed in COS-7 cells without or
proteins co-precipitating with FLAG-tagged proteins were analysed by immun
one of which comigrated with GST-Bad. The relative intensities of the upper v
2 lg) was coexpressed with wild-type GST-Bad (pEBG-mBad, 5 lg) or the
calization of these proteins was visualized by indirect immunoﬂuorescence. Sh
anti-Bad (green) antisera. Colocalization (yellow) observed in merged image
shown in the X- and Y-axis, respectively. Bar represents 10 lm.in IL-3-deprived FDCP1/Neo cells. By contrast, a third regu-
latory serine of Bad, Ser155 was phosphorylated to an equiv-
alent extent in all samples, irrespective of the presence or
absence of Pim-1 or IL-3 (data not shown). The ectopic or
endogenous expression levels of Bad were also not aﬀected
(Fig. 3A). Interestingly, when FDCP1/NT81 cells expressing
an N-terminally truncated, kinase-deﬁcient mutant of Pim-1
were analysed in parallel, phosphorylation of Bad on both1 protein was 35S-labeled by in vitro translation and incubated with
1 proteins bound to glutathione–Sepharose beads via GST-Bad were
vitro translated Pim protein sample was included as a loading control.
with FLAG-tagged Pim-1 (pcDNA3-pim-1 -FLAG, 1 lg). GST-Bad
oblotting. Shown are also the 25 kD and 50 kD IgG proteins, the latter
ersus lower bands are indicated under the ﬁgure. (C) Pim-1 (pSV-pim-1,
corresponding S112A mutant in COS-7 cells and the subcellular lo-
own are single- or double-positive cells stained with anti-Pim-1 (red) or
s was conﬁrmed by scattergrams, where green and red ﬂuorescence are
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of IL-3. Since we have previously demonstrated that the NT81
mutant sequesters wild-type Pim-1 protein into inactive olig-
omers [5] and even promotes apoptotic cell death after cyto-
kine withdrawal [10], our current results suggest that the NT81
mutant had again acted in a dominant-negative fashion to
inhibit phosphorylation of Bad by the endogenously expressed
Pim-1 kinase. Very similar results were obtained, when
FDCP1/Neo cells were transiently cotransfected with expres-
sion vectors for GST-Bad and the 33 kD isoform of Pim-1 or
the kinase-deﬁcient NT81 mutant (data not shown).
In the presence of IL-3, the ectopic expression levels for the
wild-type or mutant Pim-1 protein were not vastly higher
than those for the endogenously expressed Pim-1 isoforms
(Fig. 3A). As expected, the endogenous Pim44 and Pim33
proteins were downregulated upon IL-3 withdrawal, while the
levels for the ectopically expressed Pim44 or NT81 proteins
remained constant (Fig. 3A). However, it should be noted
that the endogenous 44 kDa isoform of Pim-1 is more stable
than the 33 kDa isoform [1] and therefore disappears more
slowly.
While our data clearly indicated that both the 44 and 33 kDa
isoforms of Pim-1 are able to phosphorylate Bad on Ser112
under both in vitro and in vivo conditions, it remained unclear
why also Ser136 phosphorylation of Bad was enhanced by wild-
type Pim-1 in FDCP1 cells and reduced by the Pim-1 mutant.
Therefore, we investigated whether Pim-1 could aﬀect Ser136
phosphorylation also when Ser112 was mutated. We expressed
S112A or S136A mutants of GST-Bad in FDCP1/Neo and
FDCP1/Pim44 cells and carried out phosphospeciﬁc Western
blot analyses with IL-3-deprived samples. When Ser112 was
replaced with an alanine residue, Ser136 was similarly dephos-
phorylated in both cell lines (Fig. 3B), indicating that Pim-1
did not directly target Ser136 under in vivo conditions. Thus,
the observed enhancement of Ser136 phosphorylation on wild-
type Bad was dependent on prior phosphorylation of Ser112 by
Pim-1 and was most likely due to activities of other kinases
targeting Ser136 such as Akt. More surprisingly, when phos-
phorylation status of the S136A mutant was analysed, no
phosphate had been incorporated into Ser112 even in theFig. 5. Pim-1 can prolong survival of IL-3-deprived FDCP1 cells also in the p
from the growth medium of FDCP1/Neo and FDCP1/Pim44 cells and sample
dead cells by propidium iodide staining. (B) FDCP1/Neo and FDCP1/Pim44
mutant (pEBG-mBad or pEGB-mBadS112A, 5 lg). 24 h after transfection, c
indicated by an arrow.presence of Pim-1 (data not shown), suggesting that there is
cross-talk to both directions between the two regulatory
phosphorylation sites. Our conclusions are further supported
by the recent ﬁnding that Ser112 acts as a gatekeeper site that
needs to be dephosphorylated ﬁrst to allow phosphatases to
access the other regulatory sites of Bad [23]. Thus, if dephos-
phorylation of Ser112 is prevented by either inhibitors against
Ser112 phosphatases such as PP2A or by constitutive activation
of Ser112 kinases such as Pim-1, Ser136 cannot be properly
dephosphorylated. Phosphorylation of Ser136 in turn is essen-
tial for the ability of 14–3–3 to bind Bad and to protect also the
other sites of Bad from dephosphorylation [15,23].
3.3. Pim-1 physically interacts and colocalizes with Bad
To examine the ability of Pim-1 to interact with wild-type or
mutant Bad proteins, we carried out in vitro binding assays
with bacterially expressed GST or GST-Bad proteins and 35S-
labeled, in vitro translated 33 kDa isoform of Pim-1 (Fig. 4A).
Hardly any binding was observed with GST alone, while both
wild-type GST-Bad and the S112A or S136A mutant proteins
bound Pim-1 at equivalent levels. These results indicate that
Pim-1 and Bad are able to directly interact with each other and
that the interaction is not dependent on the ability of Pim-1 to
phosphorylate Bad.
We next analysed intracellular interactions within COS-7
cells transiently coexpressing GST-Bad and FLAG-tagged 33
kDa isoform of Pim-1. Immunoprecipitation with FLAG an-
tibody followed by Western blotting with Bad antibody re-
vealed that GST-Bad could be coprecipitated from cells
coexpressing Pim-FLAG, but not from control cells where
only GST-Bad, Pim-FLAG or corresponding empty vectors
were expressed (Fig. 4B and data not shown).
To determine whether Pim-1 and GST-Bad proteins can
colocalize within transfected COS-7 cells, their subcellular
distribution was analysed by indirect immunoﬂuorescence as-
says. As expected, Pim-1 protein was expressed throughout the
cells, while GST-Bad localized in a punctate pattern in mito-
chondria-like organelles or in a more diﬀuse pattern in the
cytosol (Fig. 4C). Furthermore, merging of the images from
double-positive cells followed by scattergram analysis revealedresence of wild-type Bad or the S112A mutant. (A) IL-3 was withdrawn
s were collected at indicated time-points to determine the percentage of
cells were transiently transfected with wild-type GST-Bad or the S112A
ells were treated and analysed as above. The start-point of starvation is
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toplasmic compartment. Again, this colocalization was inde-
pendent of the ability of Pim-1 to phosphorylate Bad, since
similar results were obtained when the S112A mutant of GST-
Bad was coexpressed with Pim-1. Altogether, our in vitro and
in vivo results conﬁrmed that Pim-1 can colocalize and phys-
ically interact with Bad and should thereby also be able to
directly phosphorylate it.
3.4. Pim-1 can protect cytokine-deprived FDCP1 cells from
Bad-promoted apoptosis
Next we wanted to examine whether Pim-1 could protect
FDCP1 cells from the pro-apoptotic eﬀects of Bad, and whe-
ther the anti-apoptotic eﬀects of Pim-1 were in turn dependent
on its ability to phosphorylate Bad on Ser112. For this purpose,
we ﬁrst compared the survival properties of FDCP1/Neo and
FDCP1/Pim44 cell lines at several time-points after IL-3
withdrawal. Consistently with our previous observations [23],
most FDCP1/Neo cells died within three days, while more than
60% of FDCP1/Pim44 cells were still alive at that time-point
(Fig. 5A). We then transiently expressed wild-type GST-Bad
or the S112A mutant in both cell lines. As shown in Fig. 5B,
the presence of either GST-Bad protein accelerated the death
rate of cytokine-deprived FDCP1/Neo cells to a similar extent.
By contrast, the FDCP1/Pim44 cells remained relatively re-
sistant to Bad-promoted apoptosis. Furthermore, these cells
survived slightly better in the presence of wild-type Bad as
compared to the mutant. However, in both cell lines expressing
the S112A mutant, there was an initial decrease in survival
within the ﬁrst 24 h after transfection. This suggests that de-
spite the presence of IL-3, expression of the mutant had in-
hibited the ability of the transfected cells to fully recover from
electroporation and that Pim-1 could not protect cells at this
step, most likely due to its inability to phosphorylate Bad on
Ser112. While our results indicate that Pim-1 can eﬃciently
antagonize Bad-promoted cell death, and suggest that phos-
phorylation of Ser112 of Bad plays a role in Pim-dependent cell
survival, it should be noted that the results were strongly di-
luted by the fact that only about 10% of the cells had been
successfully transfected with either of the GST-Bad-expressing
plasmids (data not shown). Therefore, we attempted to select
in the presence of IL-3 for puromycin-resistant FDCP1/Neo or
FDCP1/Pim44 cell clones expressing wild-type GST-Bad or
the S112A mutant. However, no stable cell clones with full-
length S112A protein could be obtained for further analyses
(data not shown), most likely due to strong counterselection
against this potent pro-apoptotic mutant, as also observed by
others [23,24].
We have recently shown that also the Pim-2 kinase can en-
hance phosphorylation of Bad, again primarily on Ser112 [24].
Furthermore, coexpression of Pim-2 in Jurkat T-cells can
rescue part of the pro-apoptotic eﬀects of transiently overex-
pressed wild-type Bad, but less of the S112A mutant, which is
in line with the data reported here. Together these results
suggest that the Pim family kinases can share similar anti-ap-
optotic mechanisms, including inactivation of Bad. The ability
of Pim kinases to promote cell survival can in turn explain,
why both of them can eﬃciently cooperate with Myc family
transcription factors to transform hematopoietic cells [25–27],
since even though Myc-overexpressing cells have a greater
proliferation potential, they are more susceptible to apoptoticdeath, as shown also for myeloid cells [28]. Another pro-ap-
optotic protein that was recently shown to be phosphorylated
by Pim-2 is the translational repressor 4E-BP1 [29]. However,
it remains to be determined whether 4E-BP1 is a substrate also
for Pim-1 and whether its phosphorylation contributes to the
anti-apoptotic eﬀects of Pim kinases.
Yet it is clear that Pim kinases alone cannot fully protect
cells from apoptosis, since FDCP1/Pim44 cells eventually die
ﬁve days after IL-3 withdrawal [30] and FDCP1 cells stably
expressing Pim-2 isoforms do not survive any better (M. Lilly,
unpublished observation). Additional factors may thus be re-
quired in a cell type-dependent fashion. However, even if the
downstream eﬀects of Pim-1 were only transient, they may give
cells enough time to adjust to apoptotic conditions and to
gather additional mutations to allow full transformation of
cells towards apoptosis-resistant tumor cells. Interestingly, the
phenotype of Bad-deﬁcient mice resembles those of Pim-1 or
Pim-2 transgenic mice in that they develop lymphomas with
quite a long latency [31]. While Bad seems to be required to
suppress lymphoid tumorigenesis, phosphorylation of Bad
may be only one of the several mechanisms for Pim kinases to
promote cell survival and thereby also lymphomagenesis.
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